Repligen (NASDAQ:RGEN – Get Rating) updated its FY23 earnings guidance on Tuesday. The company provided EPS guidance of $2.35-$2.42 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. Wall Street Analyst Weigh In A number of […]
Geneva Capital Management LLC reduced its position in Repligen Co. (NASDAQ:RGEN – Get Rating) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,065 shares of the biotechnology company’s stock after selling 12,348 shares during the quarter. Geneva […]
Repligen (NASDAQ:RGEN – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 2nd. Analysts expect Repligen to post earnings of $0.59 per share for the quarter. Repligen has set its FY23 guidance at $2.61-2.69 EPS and its FY 2023 guidance at $2.61-$2.69 EPS.Persons that are interested in […]
Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair lifted their Q1 2023 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, April 12th. William Blair analyst M. Larew now expects that the biotechnology company will earn $0.72 per share for the quarter, up from their […]
Repligen Co. (NASDAQ:RGEN – Get Rating) shares traded up 4.3% during mid-day trading on Wednesday . The stock traded as high as $178.26 and last traded at $177.66. 322,077 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 547,335 shares. The stock had previously closed at $170.39. Analysts […]